Vexev Secures $6M Funding to Advance US Commercialisation of VxWave Robotic Ultrasound Platform

Vexev, an Australian medical robotics company, has secured US$6 million in new funding to accelerate U.S. Food and Drug Administration (FDA) 510(k) clearance and commercialisation of its VxWave robotic tomographic ultrasound platform.

The funding brings Vexev's total capital raised to more than US$19 million. The investment will support regulatory activities, manufacturing scale-up, and commercialisation efforts as the company prepares for the U.S. market.

VxWave combines robotics, artificial intelligence, and ultrasound imaging to automate vascular ultrasound acquisition. The platform is initially being developed for upper-limb imaging and dialysis vascular access applications, where patients require frequent monitoring and healthcare providers need consistent imaging workflows.

The announcement follows a multicentre clinical study with US Renal Care, one of the largest dialysis providers in the United States. The study demonstrated a 94% scanning success rate for autonomous vascular imaging performed by non-specialist clinical staff.

John Carroll, Co-founder and CEO of Vexev, stated:

"We believe high-quality vascular imaging should be available wherever patients receive care, not only when a specialist is available. We are starting with dialysis patients because the clinical need is clear, but our vision is much broader: to build an autonomous imaging platform that helps clinicians make faster, more consistent and more informed decisions across vascular disease."

Beyond dialysis vascular access, Vexev plans to expand its autonomous imaging platform into additional vascular applications, including cardiovascular and peripheral artery disease.

The funding round included participation from existing investors Blackbird Ventures, Neotribe Ventures, Startmate, and Horizon, alongside new investors TreeArc Investment Group, TEN13, Bioshore Ventures, and Alumni Ventures.